| Title | Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer |
| Authors | Ni, Jun Huang, Miao Zhang, Li Wu, Nan Bai, Chun-Xue Chen, Liang-An Liang, Jun Liu, Qian Wang, Jie Wu, Yi-Long Zhang, Feng-Chun Zhang, Shu-Yang Chen, Chun Chen, Jun Fang, Wen-Tao Gao, Shu-Geng Hu, Jian Jiang, Tao Li, Shan-Qing Li, He-Cheng Liao, Yong-De Liu, Yang Liu, De-Ruo Liu, Hong-Xu Liu, Jian-Yang Liu, Lun-Xu Wang, Meng-Zhao Wang, Chang-Li Yang, Fan Yang, Yue Zhang, Lan-Jun Zhi, Xiu-Yi Zhong, Wen-Zhao Guan, Yu-Zhou Guo, Xiao-Xiao He, Chun-Xia Li, Shao-Lei Li, Yue Liang, Nai-Xin Lu, Fang-Liang Lv, Chao Lv, Wei Si, Xiao-Yan Tan, Feng-Wei Wang, Han-Ping Wang, Jiang-Shan Yan, Shi Yang, Hua-Xia Zhu, Hui-Juan Zhuang, Jun-Ling Zhuo, Ming-Lei |
| Affiliation | Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Hosp, Beijing 100730, Peoples R China Peking Univ, Canc Hosp, Beijing, Peoples R China Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Beijing, Peoples R China Peking Univ, Int Hosp, Beijing, Peoples R China Chinese Journal Lung Canc, Beijing, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China Tianjin Med Univ, Gen Hosp, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin Lung Canc Inst, Tianjin, Peoples R China Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China Fourth Mil Med Univ, Tangdu Hosp, Xian, Peoples R China Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China China Japan Friendship Hosp, Beijing, Peoples R China China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Shenyang, Peoples R China Jilin Canc Hosp, Changchun, Peoples R China Sichuan Univ, West China Hosp, Chengdu, Peoples R China Tianjin Med Univ Canc Inst & Hosp, Tianjins Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc, Tianjin, Peoples R China Peking Univ, Peoples Hosp, Beijing, Peoples R China Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China |
| Issue Date | Mar-2021 |
| Publisher | THORACIC CANCER |
| Abstract | Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, in patients with lung cancer has increased our expectations for the success of these therapeutics as neoadjuvant immunotherapy. Neoadjuvant therapy is widely used in patients with resectable stage IIIA NSCLC and can reduce primary tumor and lymph node stage, improve the complete resection rate, and eliminate microsatellite foci; however, complete pathological response is rare. Moreover, because the clinical benefit of neoadjuvant therapy is not obvious and may complicate surgery, it has not yet entered the mainstream of clinical treatment. Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancellation of surgery, additional illness, and even death, and have therefore attracted much attention. In this article, we draw on several sources of information, including (i) guidelines on adverse reactions related to immune checkpoint inhibitors, (ii) published data from large-scale clinical studies in thoracic surgery, and (iii) practical experience and published cases, to provide clinical recommendations on adverse events in NSCLC patients induced by perioperative immunotherapy. |
| URI | http://hdl.handle.net/20.500.11897/610450 |
| ISSN | 1759-7706 |
| DOI | 10.1111/1759-7714.13942 |
| Indexed | SCI(E) |
| Appears in Collections: | 北京肿瘤医院 国际医院 人民医院 |
